ATE368116T1 - Schutzantigen des epstein-barr-virus - Google Patents

Schutzantigen des epstein-barr-virus

Info

Publication number: ATE368116T1
Authority: AT; Austria
Prior art keywords: ebna; barr virus; epstein; protective antigens; vaccine
Prior art date: 1999-08-13

Application number

AT00954003T

Other languages

English (en)

Inventor

Ralph Steinman

Christian Muenz

Original Assignee

Univ Rockefeller

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-08-13

Filing date

2000-08-10

Publication date

2007-08-15

2000-08-10 Application filed by Univ Rockefeller filed Critical Univ Rockefeller

2007-08-15 Application granted granted Critical

2007-08-15 Publication of ATE368116T1 publication Critical patent/ATE368116T1/de

Links

241000701044 Human gammaherpesvirus 4 Species 0.000 title abstract 2
239000000427 antigen Substances 0.000 title abstract 2
108091007433 antigens Proteins 0.000 title abstract 2
102000036639 antigens Human genes 0.000 title abstract 2
230000001681 protective effect Effects 0.000 title abstract 2
108010031111 EBV-encoded nuclear antigen 1 Proteins 0.000 abstract 4
229960005486 vaccine Drugs 0.000 abstract 2
206010015108 Epstein-Barr virus infection Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
230000005867 T cell response Effects 0.000 abstract 1
210000001744 T-lymphocyte Anatomy 0.000 abstract 1
210000004443 dendritic cell Anatomy 0.000 abstract 1
238000009169 immunotherapy Methods 0.000 abstract 1
208000015181 infectious disease Diseases 0.000 abstract 1
108090000623 proteins and genes Proteins 0.000 abstract 1
102000004169 proteins and genes Human genes 0.000 abstract 1
229940031626 subunit vaccine Drugs 0.000 abstract 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/46—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/16011—Herpesviridae
- C12N2710/16211—Lymphocryptovirus, e.g. human herpesvirus 4, Epstein-Barr Virus
- C12N2710/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Virology (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pharmacology & Pharmacy (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Molecular Biology (AREA)
Gastroenterology & Hepatology (AREA)
Oncology (AREA)
Biophysics (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Engineering & Computer Science (AREA)
Biotechnology (AREA)
Communicable Diseases (AREA)
Genetics & Genomics (AREA)
Biochemistry (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Micro-Organisms Or Cultivation Processes Thereof (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT00954003T 1999-08-13 2000-08-10 Schutzantigen des epstein-barr-virus ATE368116T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US14897199P	1999-08-13	1999-08-13

Publications (1)

Publication Number	Publication Date
ATE368116T1 true ATE368116T1 (de)	2007-08-15

Family

ID=22528253

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT00954003T ATE368116T1 (de)	1999-08-13	2000-08-10	Schutzantigen des epstein-barr-virus

Country Status (7)

Country	Link
EP (1)	EP1200594B1 (de)
JP (1)	JP2004500335A (de)
AT (1)	ATE368116T1 (de)
AU (1)	AU775760B2 (de)
CA (1)	CA2380991A1 (de)
DE (1)	DE60035695T2 (de)
WO (1)	WO2001012215A2 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7470428B2 (en) *	2002-01-30	2008-12-30	The Brigham And Women's Hospital, Inc.	Compositions and methods related to TIM-3, a Th1-specific cell surface molecule
AU2003236508A1 (en) *	2002-06-14	2003-12-31	Mayo Foundation For Medical Education And Research	Epstein-barr virus-specific immunization
CA2541006C (en) *	2003-10-03	2015-02-17	Brigham And Women's Hospital	Tim-3 polypeptides
CA2574282A1 (en)	2004-07-21	2006-03-02	Dana-Farber Cancer Institute, Inc.	Lentiviral vectors and uses thereof
AU2006338570B2 (en) *	2005-11-18	2013-07-11	The Ohio State University Research Foundation	Viral gene products and methods for vaccination to prevent viral associated diseases
WO2013139789A1 (en) *	2012-03-19	2013-09-26	Deutsches Krebsforschungszentrum	B-cell receptor complex binding proteins containing t-cell epitopes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP0770090A1 (de) *	1994-07-13	1997-05-02	Cornell Research Foundation, Inc.	Protein des epstein-barr virus kernantigen 1 und seine expression und anreicherung
CA2180193A1 (en) *	1995-06-28	1996-12-29	Edward Baral	Enhancing host immunity against viral infections
EP0871747A1 (de) *	1996-01-02	1998-10-21	Chiron Viagene, Inc.	Immunstimulierung vermittelt durch genmodifizierte dendritische zellen

2000
- 2000-08-10 CA CA002380991A patent/CA2380991A1/en not_active Abandoned
- 2000-08-10 JP JP2001516560A patent/JP2004500335A/ja active Pending
- 2000-08-10 DE DE60035695T patent/DE60035695T2/de not_active Expired - Fee Related
- 2000-08-10 AT AT00954003T patent/ATE368116T1/de not_active IP Right Cessation
- 2000-08-10 AU AU66362/00A patent/AU775760B2/en not_active Ceased
- 2000-08-10 WO PCT/US2000/022106 patent/WO2001012215A2/en not_active Ceased
- 2000-08-10 EP EP00954003A patent/EP1200594B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
DE60035695D1 (de)	2007-09-06
JP2004500335A (ja)	2004-01-08
WO2001012215A2 (en)	2001-02-22
DE60035695T2 (de)	2008-04-10
EP1200594A2 (de)	2002-05-02
CA2380991A1 (en)	2001-02-22
EP1200594B1 (de)	2007-07-25
WO2001012215A3 (en)	2001-08-23
AU775760B2 (en)	2004-08-12
AU6636200A (en)	2001-03-13

Similar Documents

Publication	Publication Date	Title
Long et al.	2005	CD4+ T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines
Khanna et al.	1999	Vaccine strategies against Epstein‐Barr virus‐associated diseases: lessons from studies on cytotoxic T‐cell‐mediated immune regulation
Cohen	2018	Vaccine development for Epstein-Barr virus
Rickinson et al.	1997	Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection
Münz et al.	2008	Immune escape by Epstein–Barr virus associated malignancies
Leen et al.	2001	Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4+ T-helper 1 responses
CY1106785T1 (el)	2012-05-23	Ιικα σωματιδια τα οποια απελευθερωνονται μετα απο μολυνση απο ανθρωπινο κυτταρομεγαλοϊο και η χρηση τους ως εμβολιο
Thorley-Lawson et al.	1987	Generation of specific cytotoxic T cells with a fragment of the Epstein-Barr virus-encoded p63/latent membrane protein.
Bourgault et al.	1991	Limiting-dilution analysis of the HLA restriction of anti-Epstein-Barr virus-specific cytolytic T lymphocytes
MXPA02005639A (es)	2004-09-10	Induccion de respuestas celulares iinmunologicas al virus de papiloma humano y utilizacion de composiciones de peptidos y acidos nucleico.
Zhao et al.	2024	Epstein–Barr viruses: their immune evasion strategies and implications for autoimmune diseases
Khanna et al.	1996	Peptide transporter (TAP-1 and TAP-2)-independent endogenous processing of Epstein-Barr virus (EBV) latent membrane protein 2A: implications for cytotoxic T-lymphocyte control of EBV-associated malignancies
NZ322910A (en)	2000-05-26	Tumour vaccine containing tumour cells, some with MHC-I-haplotype on cell surface to trigger immune response, and preparation of vaccine thereof
MY142842A (en)	2011-01-14	Vaccine against hpv
NO981374D0 (no)	1998-03-26	Dendrittcellestimulerende faktor
TR200200838T2 (tr)	2002-06-21	İmmunolojik olarak önemli herpes simpleks virüs antijenleri.
Duraiswamy et al.	2003	Ex vivo analysis of T-cell responses to Epstein-Barr virus-encoded oncogene latent membrane protein 1 reveals highly conserved epitope sequences in virus isolates from diverse geographic regions
MXPA02002483A (es)	2002-08-28	Vacuna contra vhb y vph.
DK1523582T3 (da)	2009-03-02	Hurtig, effektiv rensning af HSV-specifikke T-lymfocytter samt HSV-antigener identificeret derved
ATE368116T1 (de)	2007-08-15	Schutzantigen des epstein-barr-virus
UA84667C2 (ru)	2008-11-25	Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
TR200102034T2 (tr)	2001-11-21	Anti kanser aşılaması için antikorların kullanılması
Lee	2002	Nasopharyngeal carcinoma and the EBV-specific T cell response: prospects for immunotherapy
DK0882132T3 (da)	2006-03-06	Et kombineret humant cytomegalovirus-antigen og anvendelse heraf
Chen et al.	2021	T cell epitope screening of Epstein-Barr virus fusion protein gB

Legal Events

Date	Code	Title	Description
2008-01-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties